BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

UPB

Upstream Bio, Inc.
Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 31 Dec
Method
Target fiscal year · horizon from 1 Nov 2026The first fiscal year ending at least six months out is picked automatically. The target date is that year end; the return is also shown per year.

Price target projection price-to-salesDefault assumptionsDefaults: bear / bull revenue = base × (1 + lower / higher of the last two quarters’ year-on-year growth). Bear / bull P/S = 1-year low / high. Overwrite with consensus or your own view; edited figures are tagged Manual on the export.

Blue = editableeditedHover ⓘ for method and sources
Line itemBase FY2026EBear FY2027EBull FY2027EInfo
Revenue, $mRevenue, $mProjected revenue for the target year. Base FY2026E is not reported yet and locks to the annual report once it’s filed.
Revenue growth—Revenue growthVersus the base year. Type a rate to set revenue = base × (1 + growth); editing revenue updates it.
Forward P/S58.84× nowForward P/SMultiple applied at fiscal year end, when trailing revenue equals the full year. Use ▼ to pick a reference.
Diluted shares, m54.6Diluted shares, mWeighted average from the latest quarterly report. Raise it to model dilution.
Market cap, $m1862731,217Market cap, $mRevenue × P/S.
Price per share$5.00$22.28Price per shareMarket cap ÷ diluted shares. Base column shows today’s price; type your own to override it.
Weighted price targetHorizon: 14 months, to 31 Dec 2027$15.37Target return: +351.4% (14 months) +265.2% (annualized)Weighted price targetBear price × bear probability + bull price × bull probability. Upside is versus the current price ($3.41); the yearly figure annualizes it over 14 months to 31 Dec 2027.
ProbabilityBear 40%Bull 60%
Company filings + prior-close prices + your inputs · not investment advice · vpside.comData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Not investment advice. This is a model whose inputs you control; it isn’t a forecast or a recommendation to buy or sell UPB. Defaults come from the company’s filings and past prices and can be wrong; check them before relying on the result.